The long-term benefits of early intensive therapy in chronic diseases—the legacy effect
Key result
Early intensive therapy reduces long-term complications and mortality via a legacy effect.
Why the study?
The legacy effect concept has significant implications for public health and warrants in-depth research to be better understood and exploited in clinical practice, though its limitations must be considered when interpreting post-trial observational data.
Does early intensive therapy improve long-term outcomes and reduce mortality in patients with chronic diseases?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support early intensive therapy for legacy benefits in chronic diseases; confirms concept but leaves optimal strategies open.
Structured PICO
Does early intensive therapy improve long-term outcomes and reduce mortality in patients with chronic diseases?
P
Population
Patients with chronic diseases such as diabetes, hyperlipidaemia, hypertension, and chronic kidney disease (CKD)
I
Intervention
Early intensive therapy/intervention
O
Outcome
Long-term complications and mortality
Early intensive therapy in chronic diseases confers a 'legacy effect' that provides long-term protection against complications and mortality even after the intervention ends.
Limitations
- Interpreting long-term observational data collected after a clinical trial is subject to bias without appropriate study designs.
- Limitations of interpreting long-term observational data collected after a clinical trial
- Need for appropriate study designs to investigate an unbiased legacy effect
Cite This Study
Zoccali et al. (2023) conducted a review in Chronic diseases (diabetes, chronic kidney disease, hyperlipidaemia, hypertension). Early intensive therapy was evaluated. Early intensive therapy in chronic diseases provides long-term benefits, known as the legacy effect, which reduces long-term complications and mortality well after clinical trial interventions end.